Arginase type i as a marker of coronary heart disease in hemodialysis patients

International Urology and Nephrology

Volumn 43, Issue 4, 2011, Pages 1187-1194

  Eleftheriadis, Theodoros ^a,b   Liakopoulos, Vassilios ^a   Antoniadi, Georgia ^a   Stefanidis, Ioannis ^a   Galaktidou, Grammati ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Arginase; Atherosclerosis; Coronary heart disease; Hemodialysis; Inflammation; Interleukin 6; Nitric oxide; Tumor necrosis factor alpha

Indexed keywords

ARGINASE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ARGINASE; BIOLOGICAL MARKER;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PATHOGENESIS; ANALYSIS OF VARIANCE; BLOOD; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; ENZYMOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; ANALYSIS OF VARIANCE; ARGINASE; BIOLOGICAL MARKERS; CORONARY DISEASE; DIABETES MELLITUS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859930649     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9842-4     Document Type: Article

References (47)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17:2034-2047
2. Parfrey PS, Foley RN (1999) The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615
3. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD (2003) Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793-808
4. Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA (2007) Reverse epidemiology: a confusing, confounding, and inaccurate term. Semin Dial 20:586-592
5. Paraskevas KI, Kotsikoris I, Koupidis SA, Tzovaras AA, Mikhailidis DP (2010) Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. Int Urol Nephrol. doi:10.1007/s11255-010-9795-7
6. Bhan I, Thadhani R (2009) Vascular calcification and ESRD: a hard target. Clin J Am Soc Nephrol 4(Suppl 1): S102-S105
7. Patsalas S, Eleftheriadis T, Spaia S, Theodoroglou H, Antoniadi G, Liakopoulos V, Passadakis P, Vayonas G, Vargemezis V (2007) Thirty-month follow-up of coronary artery calcification in hemodialysis patients: different roles for inflammation and abnormal calcium-phosphorous metabolism? Ren Fail 29:623-629
8. Patsalas S, Eleftheriadis T, Spaia S, Theodoroglou H, Panou E, Liakopoulos V, Antoniadi G, Passadakis P, Vayonas G, Kanakis E, Vargemezis V (2005) The value of computed tomography-derived coronary artery calcifica-tion score in coronary artery disease detection in asymp-tomatic hemodialysis patients. Ren Fail 27:683-688
9. Ogawa T, Ishida H, Akamatsu M, Matsuda N, Fujiu A, Ito K, Ando Y, Nitta K (2010) Progression of aortic arch calcifi-cation and all-cause and cardiovascular mortality in chronic hemodialysis patients. IntUrol Nephrol42:187-194
10. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R (2001) Plasma concentration of asym-metrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117
11. Chicoine LG, Paffett ML, Young TL, Nelin LD (2004) Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 287:L60-L68
12. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR (2003) Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci US A 100:4843-4848
13. Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C (1997) Urea inhibits inducible nitric oxide synthase in macrophage cell line. Am J Physiol 273:C1882-C1888
14. Boger RH, Bode-Boger SM (2000) Asymmetric dimeth-ylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 26:539-545
15. Palmer RM, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526
16. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci US A 84:9265-9269
17. Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci US A 88:4651-4655
18. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R (1995) Nitric oxide modulates the expression of monocyte che-moattractant protein 1 in cultured human endothelial cells. Circ Res 76:980-986
19. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF (2000) Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell prolifer-ation. Circulation 101:1982-1989
20. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM (1994) Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 267:C1405-C1413
21. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S (1996) cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 93:1480-1485
22. Trepakova ES, Cohen RA, Bolotina VM (1999) Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res 84:201-209
23. Durante W, Liao L, Peyton KJ, Schafer AI (1998) Thrombin stimulates vascular smooth muscle cell poly-amine synthesis by inducing cationic amino acid trans-porter and ornithine decarboxylase gene expression. Circ Res 83:217-223
24. Endean ED, Kispert JF, Martin KW, O'Connor W (1991) Intimal hyperplasia is reduced by ornithine decarboxylase inhibition. J Surg Res 50:634-637
25. Durante W, Liao L, Reyna SV, Peyton KJ, Schafer AI (2001) Transforming growth factor-beta(1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation 103:1121-1127
26. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27:165-197
27. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658
28. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I (2007) Disturbances of acquired immunity in hemodialysis patients. Semin Dial 20:440-451
29. MacNaul KL, Hutchinson NI (1993) Differential expres-sion of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 196:1330-1334
30. Heo SK, Yun HJ, Noh EK, Park WH, Park SD (2008) LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett 120:57-64
31. Gross SS, Jaffe EA, Levi R, Kilbourn RG (1991) Cytokine-activated endothelial cells express an isotype ofnitric oxide synthase which is tetrahydrobiopterin-dependent, calmod-ulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macro-phages. Biochem Biophys Res Commun 178:823-829
32. Nelin LD, Nash HE, Chicoine LG (2001) Cytokine treat-ment increases arginine metabolism and uptake in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 281:L1232-L1239
33. Durante W (2001) Regulation of L-arginine transport and metabolism in vascular smooth muscle cells. Cell Biochem Biophys 35:19-34
34. Jenkinson CP, Grody WW, Cederbaum SD (1996) Com-parative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 114:107-132
35. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y (1995) Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 109:1295-1300
36. Boulanger CM, Vanhoutte PM (1997) G proteins and endothelium-dependent relaxations. J Vasc Res 34:175-185
37. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ (1992) Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 90:2092-2096
38. Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M, Grigolato P, Suzuki H, Finazzi D, Albertini A, Curello S, Ferrari R (2004) Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 37:515-523
39. Berka V, Wu G, Yeh HC, Palmer G, Tsai AL (2004) Three different oxygen-induced radical species in endothelial nitric-oxide synthase oxygenase domain under regulation by L-arginine and tetrahydrobiopterin. J Biol Chem 279:32243-32251
40. Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D (2008) Chronic inflammation and T cell zeta-chain downregulation in he-modialysis patients. Am J Nephrol 28:152-157
41. Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D (2008) Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif 26:317-321
42. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974
43. Rask-Madsen C, King GL (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:46-56
44. Kannel WB, McGee DL (1979) Diabetes and cardiovas-cular risk factors: the Framingham study. Circulation 59:8-13
45. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Asso-ciation and the American College of Cardiology. Circula-tion 100:1481-1492
46. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ (2002) Traditional cardiovascular dis-ease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13:1918-1927
47. Devaraj S, Dasu MR, Jialal I (2010) Diabetes is a proin-flammatory state: a translational perspective. Expert Rev Endocrinol Metab 5:19-28